Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
37
MNOV Quote, Financials, Valuation and Earnings
Last price:
$1.35
Seasonality move
:
11.21%
Day range:
$1.41 - $1.47
52-week range:
$1.13 - $1.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
161.67x
P/B ratio:
1.60x
Volume:
20.5K
Avg. volume:
59.7K
1-year change:
-2.74%
Market cap:
$66.4M
Revenue:
$409.7K
EPS (TTM):
-$0.24
Analysts' Opinion
-
Consensus RatingMediciNova, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, MediciNova, Inc. has an estimated upside of 640.74% from its current price of $1.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $1.42.
Fair Value
-
According to the consensus of 2 analysts, MediciNova, Inc. has 640.74% upside to fair value with a price target of $10.00 per share.
MNOV vs. S&P 500
-
Over the past 5 trading days, MediciNova, Inc. has underperformed the S&P 500 by -1.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MediciNova, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MediciNova, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter MediciNova, Inc. reported revenues of $151.7K.
Earnings Growth
-
MediciNova, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter MediciNova, Inc. reported earnings per share of -$0.06.
Enterprise value:
35.9M
EV / Invested capital:
0.86x
Price / LTM sales:
161.67x
EV / EBIT:
--
EV / Revenue:
87.51x
PEG ratio (5yr expected):
-0.65x
EV / Free cash flow:
-3.65x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$30.7K
Return On Assets:
-23.87%
Net Income Margin (TTM):
-2928.48%
Return On Equity:
-25.55%
Return On Invested Capital:
-25.38%
Operating Margin:
-2038.5%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $1M | -- | $409.7K | -- | $151.7K | |
| Gross Profit | $881.1K | -$21.1K | -$30.7K | -$5.2K | $200 | |
| Operating Income | -$9.9M | -$12.7M | -$13.3M | -$3.2M | -$3.1M | |
| EBITDA | -$9.8M | -$12.7M | -$13.2M | -$3.2M | -$3M | |
| Diluted EPS | -$0.17 | -$0.23 | -$0.24 | -$0.06 | -$0.06 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $72M | $59M | $51.2M | $41.1M | $31M | |
| Total Assets | $87.4M | $74.2M | $66.3M | $55.9M | $45.6M | |
| Current Liabilities | $2.8M | $3.2M | $3.3M | $3M | $3.8M | |
| Total Liabilities | $3.7M | $3.9M | $3.9M | $3.4M | $4M | |
| Total Equity | $83.7M | $70.2M | $62.4M | $52.5M | $41.6M | |
| Total Debt | $694.7K | $523.6K | $410.7K | $211.5K | $17.1K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.4M | -$10.6M | -$9.8M | -$1.9M | -$2M | |
| Cash From Investing | $39.9M | -$700 | -$2.9K | -- | -- | |
| Cash From Financing | -- | -- | $244K | -- | $244K | |
| Free Cash Flow | -$7.5M | -$10.6M | -$9.8M | -$1.9M | -$2M | |
MNOV
Sector
Market Cap
$66.4M
$25.1M
Price % of 52-Week High
68.88%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
-0.3%
-1.6%
1-Year Price Total Return
-8.16%
-18.38%
Beta (5-Year)
0.575
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.39
200-day SMA
Buy
Level
$1.39
Bollinger Bands (100)
Sell
Level
1.32 - 1.62
Chaikin Money Flow
Buy
Level
17.7K
20-day SMA
Sell
Level
$1.46
Relative Strength Index (RSI14)
Sell
Level
45.41
ADX Line
Buy
Level
19.93
Williams %R
Neutral
Level
-78.8955
50-day SMA
Sell
Level
$1.53
MACD (12, 26)
Buy
Level
0.31
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
159.3K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.0736)
Buy
CA Score
(Annual)
Level (0.3184)
Buy
Beneish M-Score
(Annual)
Level (-4.6604)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.4774)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
Stock Forecast FAQ
In the current month, MNOV has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MNOV average analyst price target in the past 3 months is $10.00.
-
Where Will MediciNova, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that MediciNova, Inc. share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About MediciNova, Inc.?
Analysts are divided on their view about MediciNova, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MediciNova, Inc. is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is MediciNova, Inc.'s Price Target?
The price target for MediciNova, Inc. over the next 1-year time period is forecast to be $10.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MNOV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MediciNova, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MNOV?
You can purchase shares of MediciNova, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MediciNova, Inc. shares.
-
What Is The MediciNova, Inc. Share Price Today?
MediciNova, Inc. was last trading at $1.35 per share. This represents the most recent stock quote for MediciNova, Inc.. Yesterday, MediciNova, Inc. closed at $1.42 per share.
-
How To Buy MediciNova, Inc. Stock Online?
In order to purchase MediciNova, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MNOV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MNOV
Sector
P/E ratio
--
21.37x
PEG ratio
-0.65x
-0.01x
P/B ratio
1.60x
1.73x
Price / LTM sales
161.67x
1.46x
Growth Metrics
MNOV
Sector
Revenue growth
--
3.27%
Earnings growth
0.7%
12.13%
Revenue (5-year growth)
--
6.25%
Earnings forecast
-$0.10
-$0.20
Profitability
MNOV
Sector
Profitability FY 2025
$11K
$2.3M
Return on invested capital
-25.38%
-33.43%
Return on assets
-23.87%
-29.94%
Return on equity
-25.55%
-40.07%
Earnings Date
Last Earnings Date
Feb
20
Next Earnings Date
May
13
Estimated Next Earnings Date
May
22
Balance Sheet
MNOV
Sector
Total cash
$30.8M
$24.9M
Short term investments
--
$23M
Total assets
$45.6M
$70.1M
Long term debt
$17.1K
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
